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I. ABSTRACT
Ischemia stimulates heart GLUT4 and GLUT1 translocation and glucose uptake
in vivo. Stimulation of AMP-activated protein kinase (AMPK), an enzyme which
mediates many of the effects of ischemia and which has been described as a cellular “fuel
gauge,” with 5-aminoimidazole-4-carboxamide-l-ribofuranoside (AICAR) increases 2deoxyglucose uptake and causes GLUT4 translocation in isolated cardiac papillary
muscles. AMPK activation may also increase heart FFA uptake in vitro. In order to
study the effects of specific cardiac AMPK activation on GLUT translocation and heart
substrate metabolism in vivo, we selectively infused AICAR (12.5mg/min x 90 min)
intra-arterially into the anterior, LAD region of the heart in 8 anesthetized dogs. AICAR
increased myocardial AMPK activity 3-fold in the anterior region compared to the
posterior control region. AICAR increased the myocardial uptakes of glucose (2.3 fold)
and free fatty acids (1.4 fold), but did not alter heart lactate or oxygen uptake. AICAR
did not alter the energetics of the myocardium and the myocardial concentrations of
ATP, AMP, ADP and creatine phosphate, which normally regulate AMPK activity, did
not change. Cell fractionation and subsequent immunoblotting of purified membrane
fractions demonstrated AICAR-induced translocation of both GLUT4 (1.8 fold, p<0.002)
and GLUT1 (1.7 fold, p<0.001) from intracellular membranes in sarcolemma. Therefore,
AMPK activation by regional AICAR infusion increased myocardial glucose uptake and
caused translocation of both GLUT1 and GLUT4 in vivo without changing cellular
energetics. AICAR also modestly increased heart FFA uptake consistent with the known
effect of AMPK to inhibit acetyl CoA carboxylase. These findings support the

hypothesis that ischemia-induced increases in heart glucose uptake and glucose
transporter translocation may be mediated by activation of AMPK.
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II. INTRODUCTION
Myocardial Glucose Metabolism

Cardiovascular disease, largely in the form of ischemic heart disease, is the
leading cause of death in the developed world and in the next two generations will also
become the leading cause of mortality in the third world. [Organization, 1998 #1] The
past few decades have brought significant advances in the diagnosis and treatment of
ischemic heart disease, both acutely during an episode of myocardial ischemia and
chronically in optimizing cardiac function in the diseased heart and preventing further
episodes of ischemia or cardiac death.

Cholesterol control, hypertension management,

procedures to revascularize ischemic myocardium, a wide array of pharmacological
agents for hemodynamic control and other measures have given clinicians many tools to
control ischemic heart disease. Recently, the understanding that clot formation plays a
central role in the sudden loss of perfusion in myocardial ischemia has also led to the
development of various thrombolytic therapies to quickly reperfuse myocardium. The
observation that the revascularized, optimally loaded heart displays continued
dysfunction following thrombolysis even while it remains viable has highlighted the role
of metabolic derangement in myocardial ischemia and renewed interest in the metabolic
changes that accompany ischemia and their contribution to contractile dysfunction.
[Taegtmeyer, 1995 #3]
Like all muscle, the heart functions to convert chemical energy into mechanical
energy for pumping blood. The energy for this comes from metabolic substrate
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oxidation which requires oxygenated blood and sufficient metabolite delivery.

While

the heart comprises just 0.5% of body weight it receives 4% of cardiac output and
accounts for 10% of oxygen consumption. To meet its energy requirements the 300g
heart uses a large amount of energy producing 35kg of ATP per day. [Willerson, 1995
#2] The myocardium uses free fatty acids (FFA) and glucose for substrate during aerobic
metabolism. The choice of substrate depends on arterial concentrations and is also
influenced by hormones, workload and oxygen availability. [Willerson, 1995 #2] This
leads to a preference for FFA during fasting, glucose after meals and lactate and FFA
during exercise. The myocardium can also use ketone bodies and even amino acids to
produce energy and under certain conditions also uses endogenous energy sources such
as glycogen and triglycerides. [Taegtmeyer, 1995 #3]
Glucose metabolism in myocardium, as in all tissues has two main components,
glycolysis and glucose oxidation. Glycolysis can produce ATP without oxygen and
while it usually contributes less than 10% of the ATP in non-ischemic conditions, it has
a special role in maintaining the ion potential in the cell membrane. [Oliver, 1994 #4]
Glucose is converted to pyruvate during glycolysis and once inside mitochondria,
pyruvate dehydrogenase produces acetyl Co A which enters the TCA cycle generating
reducing equivalents which are oxidized to produce ATP and water. Glucose can also be
converted to glycogen under regulation of glycogen synthase or enter the pentose
phosphate shunt to produce NADPH and ribose. Oxidation of fatty acids is the other
main source of acetyl CoA production in mitochondria but is slightly less efficient than
glucose oxidation requiring a greater amount of oxygen to produce each ATP.
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During myocardial ishcemia, there is compromised tissue perfusion and oxygen
delivery. However, residual anterograde perfusion and collateral blood flow maintains
some residual availability of oxygen and substrate. [Willerson, 1995 #2] Anaerobic
glycolysis becomes important in the production of a limited amount of ATP which along
with residual glucose oxidation may or may not be capable of maintaining function.
There is a shift away from aerobic fatty acid oxidation and an accumulation of fatty
acids. [Lopaschuk, 1998 #5] In severe ischemia, catecholamines also stimulate lipolysis
in adipocytes and contribute to a rise in fatty acids. [Goodwin, 1994 #8] This elevation in
fatty acids may be arrythmogenic and contribute to depressed cardiac function.
[Lopaschuk, 1998 #5; Goodwin, 1994 #8] Glycogen stores, are also depleted following
severe ischemia.

In addition, TCA intermediates are depleted when lactate, alanine and

succinate accumulate and glutamate disappears. [Taegtmeyer, 1995 #3]
Facilitative Glucose Transporters
The greater utilization of glucose requires higher rates of glucose uptake.
Enhanced uptake is accomplished through greater transport of glucose through facilitative
glucose transporters. The family of facilitative glucose transporters (GLUTs) are passive
carriers which transport glucose in an energy-independent system that moves down a
concentration gradient. [Muekler, 1994 #9] Unlike the Na7glucose transport in intestine
and kidney, the reaction is thermodynamically downhill and requires no energy. GLUTs
mediate the exchange of glucose between the blood and cytoplasm and drive the balance
of glucose concentrations between blood, the interstitial space and the cells.

Once inside

the cell, glucose is phosphorylated by hexokinase and in the absence of glucose-6phosphatase in muscle, it remains within the cell.

8

Seven mammalian glucose transporter isoforms have been identified. They have
12 membrane spanning helices with about half of the amino acid residues within the
phospholipid bilayer of cellular membranes. [Stephens, 1995 #10] They exhibit tissue
specificity and developmental related expression and in the adult mammalian heart,
GLUT4 and GLUT1 are the primary isoforms expressed. [Fischer, 1997 #21] In heart and
skeletal muscle, GLUT1 mRNA and protein decrease during development while GLUT4
show increases. [Wang, 1991 #12; Santalucia, 1992 #13] GLUT1 is found primarily in
cardiac myocytes of the ventricle and it controls basal glucose utilization when insulin
concentrations are low and there is normal work demand.

Studies in brain show that the

Km of GLUT1 is ImM and thus GLUT1 has transport activity at normal glucose
concentrations of approximately 4-8mM. [Stryer, 1995 #84; Holloszy, 1996 #19]
GLUT4 has a Km of 5mM and while it also has some basal activity its key role is to
respond to external stimuli. It therefore plays a greater role in effecting changes in
glucose uptake.
Kinetic studies have shown that insulin and other stimuli such as ischemia
increase the Vmax of glucose transport. [Cushman, 1980 #11] This increase in Vmax can be
caused by either an increase rate of turnover or by a greater availability of transporters at
the cellular membrane. Membrane fractionation studies have established that most of the
enhanced uptake is due to a shift of glucose transporters from intracellular pools where
they are inactive to the sarcolemma where they can facilitate glucose uptake[Stephens,
1995 #10] Unlike other insulin sensitive tissue such as adipocytes and skeletal muscle,
glucose uptake in myocardium is stimulated by translocation of both GLUT4 and
GLUT1 from intracellular pools to the sarcolemma in response to insulin and ischemia.
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[Young, 1995 #79] However, the degree of translocation is greater for GLUT4.
Translocation of glucose transporters to the T-tubule system also enhances uptake in
muscle and is important in stimulating glucose uptake. [Dombrowski, 1996 #22; Roy,
1996 #23]
The AMP-activated Protein Kinase (AMPK)
Myocardial ischemia causes an increase in glucose uptake through the
translocation of the facilitative glucose transporters GLUT4 and GLUT1 from an
intracellular pool to the sarcolemma through an undetermined mechanism. In addition, it
causes activation of the AMP activated protein kinase (AMPK) [Kudo, 1995 #36; Kudo,
1996 #24]. AMPK was first discovered over two decades ago and is highly preserved in
all eukaryotes including mammals, fungi and plants. [Hardie, 1997 #28] AMPK has been
proposed to play a central protein in the cellular response to changing metabolic
conditions All mammals express a similar form of AMPK while in fungi and plants
AMPK homologues such as SNP, a kinase involved in the regulation of cellular
metabolism, are expressed. [Mitchelhill, 1994 #33] [Carling, 1989 #31] Unlike most
kinases, AMPK serves not as a signal of extracellular messengers but rather as a way for
the cell to respond to environmental stress causing a compromise of energetic and
metabolic conditions within the cell. It has been described as a “fuel gauge” or a “low
fuel warning system” for the cell signaling low levels of ATP and high energy
phosphates caused by stress. [Hardie, 1994 #25] Stresses such as heat shock, hypoxia or
oxidative stress impair the ability of mitochondria to rephosphorylate ADP to ATP
causing an increase in the ADP to ATP ratio which in turn activates AMPK as AMP
level rise. This causes an increase in the ADP to ATP ratio and an even larger increase in
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the AMP to ATP ratio through the action of adenylate kinase which catalyses the
conversion of ADP into AMP and ATP. The rise in AMP levels activates AMPK and
inactivates regulatory enzymes in biosynthetic pathways and increases flux through
catabolic pathways thereby preserving ATP for short term needs. [Corton, 1995 #26]
Studies of purified enzyme show that AMPK is highly specific for AMP and the
enzyme can only be activated by AMP or its analogs. AMP affects the AMPK system in
four distinct ways (figure 1) [Hardie, 1997 #28; Corton, 1995 #26] First, it binds AMPK
and causes direct allosteric activation. When the enzyme is in a phosphorylated state,
allosteric activation by AMP causes a five fold increase in its activity. Second, AMP
binds to dephosphorylated AMPK and makes it a better substrate for AMPK kinase
(AMPKK). Phosphorylated AMPK has about a 50-fold greater activity than nonphosphorylated AMPK. Third, it binds to phosphorylated AMPK and makes it a worse
substrate for protein phosphatase 2C (PP2C), an enzyme which is responsible for almost
all the phosphatase activity of AMPK. Finally, AMP binds to and activates AMPKK.
However, it is likely that AMPK activity is not determined by AMP alone. ATP
levels are known to independently influence the activity of AMPK. [Hardie, 1997 #28;
Corton, 1995 #26; Davies, 1989 #7] In muscle, the creatine kinase-phosphocreatine (CrPCr) system acts as an energy buffer to provide ATP during contraction and maintains
the ATP:ADP ratio within myocytes. Recently, a decrease in the PCr:Cr ratio has been
shown to increase AMPK activity in skeletal muscle. [Ponticos, 1998 #27] This is
consistent with the role of AMPK in mediating a response to changes in energy state and
to the important role of the creatine system in the energetics of muscle. It is likely that
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this observation can be extended to cardiac muscle as well, given the similarity of the
creatine system in cardiac muscle.
AMPK was initially isolated from the liver as a kinase causing the
phosphorylative deactivation of HMG-CoA reductase, the regulatory enzyme of sterol
synthesis, and inhibiting sterol synthesis (and was dubbed HMG-CoA reductase kinase).
[Ingebristen, 1978 #29] Subsequently, it was found to phosphorylate and inhibit acetyl
CoA carboxylase and decrease malonyl-CoA. [Carling, 1987 #30] This decreases fatty
acid synthesis while stimulating fatty acid oxidation by increasing camitine-palmitoyl
transferase 1 (CPT1) and promoting entry of fatty acids into mitochondria, (figure 2) In
the metabolism of glycogen, AMPK inhibits glycogen synthase and stimulates glycogen
phosphorylase decreasing synthesis and stimulating breakdown. [Vincent, 1996 #45] The
primary role of AMPK was therefore believed to be in the regulation of these synthetic
pathways either through feedback or hormonal mechanisms. However, none of the
products of these pathways has been shown to cause changes in it activity and it is not
subject to hormonal regulation. These actions of AMPK should therefore be viewed in
light of its role in responding to changing cellular metabolic conditions and it function in
increasing flux through energy producing catabolic pathways while decreasing activity
through energy consuming anabolic pathways. Further study is likely to reveal more
roles for AMPK in the energy metabolism of the cell.
The hypothesis that AMPK protects cells against stresses that deplete ATP
suggests that it may be involved in many other processes. Studies in yeast have provided
insight into other potential roles of AMPK. [Hardie, 1994 #25; Hardie, 1997 #28]
Mutations in the mammalian AMPK homologue SNF1 and SNF4 genes of yeast show
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that they are necessary for derepression of cytochrome oxidase genes required for
oxidative metabolism and for expression of genes necessary for growth in the absence of
glucose. In addition, they cause the phosphorylated inactivation of yeast acetyl-CoA
carboxylase and are involved in cell cycle regulation. [Mitchelhill, 1994 #33] These
findings suggest that the AMPK system is highly conserved and also plays a role in gene
expression. Recently, the initial demonstration of AMPK activation of a mammalian
gene has been made in hepatocytes where AMPK activation caused repression of the rat
fatty acid synthase gene. [Foretz, 1998 #78]
AMPK has three subunits named a (63kD), (3, and 5. (Davies) The a subunit is
the catalytic subunit and shows a clear similarity to the SNF1 gene of the yeast
saccharomyces cervisiae and other SNF1 related gene products from plants. It contains
the site (Thr 172) for phosphorylation by AMPKK. [Hardie, 1997 #28] Two homologous
isoforms of the a subunit, al and a2 have been identified. Recent studies have shown
that the a2 variety has greater activity and is found in the highest levels in liver and
skeletal and cardiac muscle. [Stapleton, 1996 #38] The specific distribution of the two
may play a role in modulating the AMPK activity and thus, the tissue response to
ischemia or other environmental stresses.
Potential Role of AMPK Activation in Glucose Transport
Two findings suggest that AMPK may be mediate the effects of myocardial
ishcemia on glucose metabolism. First, AMP levels are known to rise during exercise in
skeletal muscle [Hutber, 1997 #39] and in ischemic myocardium [Reibel, 1978 #40] and
cause activation of AMPK in both skeletal muscle during exercise/contraction [Hutber,
1997 #39] and myocardial ischemia. [Kudo, 1995 #36] Rising AMP levels are also
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accompanied by lower concentrations of phosphocreatine.

Both high AMP and lower

phosphocreatine levels are known to activate AMPK. Second, ischemia/exercise induced
increase in glucose uptake and GLUT 1 and GLUT 4 translocation is mediated through a
pathway that is distinct from the PI3 kinase dependent translocation found with insulin.
[Egbert, 1997 #41; Lund, 1995 #43] AICAR, a pharmacological activator of AMPK,
also induced increase in glucose uptake that are independent of the PI3K
pathway[Russell, 1998 #44; Hayashi, 1998 #50] and like ischemia are additive to insulin
driven increases in glucose uptake [Russell, 1998 #44; Hayashi, 1998 #50]
AICAR is a structural analog of adenosine (figure 3). It is taken up by cells and
monophosphorylated by adenosine kinase to form AICARibotide or ZMP. ZMP
activates AMPK mimicking the effects of AMP on AMPK without affecting the stores
of ATP, ADP, and AMP and the relevant ratios that normally control AMPK activity
[Henin, 1996 #48]. The activated AMPK has similar physiologic effects as when AMP
levels rise including inhibition of ACC and decrease in malonyl-CoA [Merrill, 1997 #51]
and increased fatty acid oxidation.
Recently, AICAR has been shown to increase glucose uptake in perfused
hindlimb muscles. [Merrill, 1997 #51] This laboratory has also demonstrated that
incubation of isolated papillary muscles in AICAR causes enhancement of glucose
uptake and translocation of GLUT4 glucose transporter [Russell, 1998 #44] These
findings were limited by the in vitro nature of the study which allowed for the
observation of the effects of AICAR on quiescent myocardial tissue not performing work.
There was also no substrate competition and the uptake of deoxyglucose which does not
enter any of the glucose metabolic pathways following phosphorylation was used to

Adenosine

AICAR

17

estimate glucose uptake.

Evidence of translocation was limited because it was only seen

in qualitative immunoflorescence studies and in poor quality membrane fractions (only 56 fold enrichment of sarcolemmal membranes) [Russell, 1998 #44]. The findings from
these membrane studies were further limited by the increase systemic lactate
concentrations caused by the systemic AICAR infusion.
In order to study the in vivo effects of AMPK activation by AICAR on glucose
metabolism in vivo we infused AICAR in a selected region of the heart in dogs. This
model offers several advantages. First, the direct infusion of AICAR into the coronary
arteries allows a higher dose of AICAR and therefore greater activation of AMPK in
myocardium without the systemic effects of high AICAR concentrations such as a
buildup of lactate. This will enable a more clear interpretation of the effects of AMPK
activation without the concern for the confounding effects of significant changes in
substrate concentrations. Second, the large scale of the experiment allows for direct
measurement of myocardial glucose uptake. Third, sufficient tissue can be obtained for
membrane fractionation to study effects on glucose transporters and the use of a canine
model also provides highly enriched membrane fractions. [Young, 1995 #79] Finally,
physiologic parameters can also be closely followed.
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III. METHODS
Animal Preparation and Experimental Protocol
Experiments were performed on fasting male mongrel dogs (40-60 lbs) according
to a protocol approved by the Yale Animal Care and Use Committee. The animals (n=8)
were anesthetized with sodium thiopental (70 mg/kg), intubated, and ventilated with
halothane (1% to 2%), nitrous oxide (70%), and oxygen (30%) to maintain adequate
anesthesia and oxygenation throughout the procedure.
As previously described, [Shi, 1995 #16; Edwards, 1992 #15] the heart was exposed
through a left lateral thoracotomy. Polyethylene catheters with 25 gauge needle ends
were placed in the proximal left anterior descending coronary artery (LAD) for
intracoronary infusion and in the cardiac veins draining the left circumflex coronary
artery (LCX) regions and LAD for venous blood sampling. [Shi, 1995 #16] Doppler
crystals were sutured to the epicardial surface to measure myocardial thickening within
the LAD and LCX regions using fine suturing material. A micromanometer catheter was
placed to measure left ventricular pressure and dP/dt. A left atrial catheter was placed for
injection of microspheres to measure coronary blood flow. Core temperature was
maintained with heating pads and covering sheets.
After animal preparation, four baseline samples of arterial and LAD and LCX
cardiac venous blood (4-5ml) were made over 20 minutes. Microspheres were then
injected in order to measure blood flow. [Shi, 1995 #16; Edwards, 1992 #15] Small
quantities of different isotopes were used for each time period. The microspheres do not
affect flow or subsequent myocardial function. Hemodynamic parameters including heart
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rate, aortic and left ventricular (LV) blood pressure, LV dP/dt, and cardiac output were
recorded. Hemodynamic measures were recorded with data acquisition software
(Dataflow, Crystal Biotech). AICAR was then infused into the proximal LAD at a rate
of 12.5mg/min. (0.25ml/min) Repeat metabolic and hemodyanamic measurements were
made at 30-45 minutes and at 75-90 minutes after the start of the AICAR infusion. The
heart was then excised and samples (~0.5g) of tissue were taken from the central LAD
and LCX regions and frozen in liquid nitrogen for AMPK activity determination. The
remainder of the left ventricle was then placed in ice cold saline and utilized for
membrane preparation and immunofluorescence as described below.
Analytic Measurements
Arterial and selected anterior and posterior cardiac venous blood was centrifuged
and analyzed for plasma glucose and lactate concentrations with a glucose/lactate
analyzer (Yellow Springs Instruments). Oxygen content in whole blood was measured
with a hemoximeter (OSM 3, Radiometer America, Inc.). Plasma FFA was measured
with a spectrophotometric assay (Waco) and AICAR concentrations were determined
using a spectrophotometric assay which uses a diazotization coupling technique with N(l-naphthyl)ethylenediamid. [Fujitaki, 1994 #42] The assay is adopted from established
methods for the detection of primary aromatic amides and correlates to high degree
(correlation coefficient of 0.98) with HPLC measurements and has a good sensitivity
down to a concentration of 0.25|ig/ml.
Myocardial AMP, ZMP, ADP and ATP concentrations in tissues were measured
by HPLC according to a previously utilized protocol. [Sabina, 1982 #52]

Approximately

1 OOmg of frozen tissue was pulverized and homogenized in 4 times volume of 6%
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perchloric, centrifuged at 3000g for 10 minutes at 4° C and neutralized with 3 M K
HCO3. Samples were then filtered and diluted 1:10 before running on HPLC system
(with Systom Gold software) eluting buffers of 5mM NH4H2PO4, pH 2.8 initially and
changing to 750mM NH4H2PO4, pH 3.9 beginning at 14 min period of 35 minute run and
increasing linearly. Desired peaks were identified and quantified by comparison with
standards.
Myocardial glycogen concentrations were determined using a method used by
Walass et al. [Walaas, 1950 #46]

Briefly, 20-40mg of tissue were solubilized in 200pJL

30%KOH at 70° C and glycogen was precipitated overnight by the addition of lOOpL of
6% Na2SC>4 and 700fiL of methanol. After centrifugation, the pellet was washed with
methanol and resuspended in 500|iL 0.5 M sodium acetate (pH 4.8) with 2mg/mL
amyloglucosidase. (sigma) After incubation for 90 min at 40° C the glucose
concentration was determined.
Myocardial glucose phosphate levels were measured using a spectrophotometric
assay. [Lang, 1974 #85] Tissue extracts were mixed with 0.2M Tris, pH 7.5, 0.1M
MgCb and 1% NADP and absorbance was measured both prior to and following the
addition of the enzyme glucose-6-phosphate dehydrogenase (1 pig/pil). Various of
concentrations of glucose-6-phosphate were assayed to estimate a standard curve. Citrate
concentrations were measured using a spectrophotometric assay (Boerhinger Mannheim).
PCA extracts were treated with citrate lyase, malate dehydrogenase, and lactate
dehydrogenase which converted citrate to oxaloacetate and then lactate and in the process
produced NAD+ from NADH and causing a change in absorbance. This change in
absorbance was used to calculate the citrate concentration. Creatine phosphate was
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measured from PCA extracts in 50mM triethanolamine, pH 7.5, 13mM NADP, 0.1M
MgCh, 0.5M glucose, and 21mM ADP in the presence of creatine kinase, hexokinase and
G6P dehydrogenase. [Heinz, 1983 #49] This reaction converts NADP+ to NADPH
causing a shift in absorbance from which the creatine phosphate concentration can be
calculated.
Membrane Preparation and Characterization
Left ventricular myocardium from the anterior region infused with AICAR and
from the control posterior ventricular wall (approximately 25g each) was selected. The
border zone between the two regions was discarded. Membrane fractions were prepared
as described previously using differential and sucrose gradient centrifugation. [Russell,
1998 #20; Young, 1995 #79] In brief, crude homogenates (20%wt/vol) were prepared in
NaHC03 (lOmM) / NaN3 (5mM) buffer with a polytron and centrifuged at 1200g for 10
minutes. The pellet was resuspended and rehomogenized and centrifugation was
repeated.

The supernatant (crude membrane fraction) was centrifuged at 190,000 g for 1

hour, resuspended in a 25% sucrose solution and loaded onto a discontinuous sucrose
gradient (25%, 30%, 35% wt/vol) and centrifuged for 18 hours at 150,000g. The
sarcolemma fraction was collected from the upper half of the 25% sucrose layer The
intracellular membrane fraction was collected from the 30%/35% interface. The
membranes were collected and diluted 4-5 fold in NaHC03 (10mM/NaN3 5mM) and
then centrifuged at 190,000g for 1 hour. All procedures were done at 4° C. The
membranes were resuspended in Tris (50mM), pH 7.4 and stored at -70° C. There was
no statistically significant difference in the protein yields between AICAR and control
regions, (table 1)
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Table la. Enrichment of Membrane Fractions
Enrichment vs. crudemembrane*

Fraction

Marker

Intracellular

Ca~ ATPase

Control: 8.8 (+/- 2.59)
AICAR: 8.0 (+/-2.51)

Sarcolemmal

Na+/K+ ATPase

Control: 239 (+/- 110)
AICAR: 84 (+/- 14)

Values are expressed as mean +/- SEM. * AICAR vs Control not statistically significant
for both fractions.

Table lb. Protein Yield Membrane Fractions
Fraction

Yield (fig)*

Intracellular

Control:
AICAR:

1022 (+/-285)
955 (+/- 245)

Sarcolemmal

Control:
AICAR:

475 (+/- 57)
490 (+/- 63)

Values are expressed as mean +/- SEM. * AICAR vs Control not statistically significant
for both fractions.

23

Membrane protein concentration was measured with a spectrophotometric assay
(Bio-Rad Laboratories) using bovine serum albumin as a standard. Enrichment of
fractions for the sarcolemma and sarcoplasmic reticulum proteins, Na+, K+-ATPase and
Ca^-ATPase, respectively, was assessed by immunoblot analysis of the membrane
fractions with monoclonal antibodies to the B-subunit of the Na+, K+-ATPase (gift from
Dr. Michael Caplan) and the SERCA-2 calcium pump (Affinity Bioreageants, Inc).
Immunoreactive protein was detected and quantified with

-I-antimouse IgG

(Amersham Co). Sarcolemmal membranes were highly enriched for the plasma
membrane marker Na+, K+-ATPase (80-240 fold when compared with crude fractions)
while the intracellular fractions were enriched for the intracellular marker Ca^-ATPase.
(about 8 fold relative to crude membrane fraction). There was no statistically significant
difference in these enrichments, (table 1)

GLUT 4 and GLUT 1 Immunoblot Analysis
Sarcolemma and intracellular membrane proteins (20pig) underwent SDS-PAGE
on 10% and were transferred to PVDF membranes. [Young, 1995 #79] (Bio-Rad
Laboratories) Membranes were blocked with 5% non-fat milk in PBS and then
incubated with polyclonal GLUT4 that was partially purified in an IgG column (1:5000)
or GLUT1 in whole serum (1:1000) antibodies with specific immunoreactivity in canine
heart ( LHY1 ) overnight at 4° C. The membranes were washed and incubated with 125-Iprotein A, washed again prior to autoradiography and then quantified using a gamma well
counter (Packard Instruments).

AMPK was assayed using a previously described method which measures the
phosphorylation of a purified 17 amino acid peptide containing the consensus sequence
(SAMS) for AMPK. [Winder, 1996 #34] Approximately lOOmg of tissue was
homogenized in 5x volume of isolation buffer containing lOOmM Tris-HCl, pH 7.5,
ImM EDTA, ImM EGTA, lmM DTT, ImM benzamidine, 400pg/ml trypsin inhibitor,
50mM NaF, 5mM sodium pyrophosphate, 10% v/v glycerol.

Homogenates were

centrifuged at 14,000g for 30 min, polyethylene glycol 8000 (PEG) was added to the
supernatant to achieve a concentration of 2.5% (w/v) and then centrifuged at 10,000g for
10 min. PEG was then added to bring to a final concentration of 6% (w/v), centrifuged
again at 10,000g, and the pellet was finally resuspended in lOOpl of homogenization
buffer. Aliquots were taken to determine protein concentration and samples were stored
in liquid nitrogen and stored for a maximum of 1-3 days.
Isolated protein (2pg) was incubated in buffer containing 96mM Hepes-NaOH,
pH 7.9, 192mM NaCl, 20%glycerol, 240mm SAMS, 2.4mmAMP, 5mM MgCf, 200p.M
ATP with 200-400 dpm/pmol 32P ATP (Lopachuk 2) at 30°C for 5 minutes. Aliquots
were then removed and spotted on phosphocellulose filter paper (Whatman P81), washed
4 times with 150mM phosphoric acid over 30 minutes and once in acetone for 20
minutes, dried and counted with liquid scintillation fluid . AMPK activity was
determined after subtaraction of background activity.
Calculations and Statistical Analysis
Myocardial blood flow was calculated according to the following equation:
Blood flow = (dpm/mg)'1*(dpm/ml)*(ml)*(sec)'1
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The [ (dpm/mg) is obtained from counting samples of tissue, (dpm/ml) is calculated from
the ratio of known quantity of isotope to measured quantity of blood, ml is injected
volume, and time is also carefully measure (45 seconds)].
The myocardial uptake of glucose, lactate, and FFA were calculated as the
product of the cardiac extractions (AV concentration difference) and the myocardial
plasma flow. Plasma flow was in turn calculated from the blood flow and individually
hemoglobin concentrations. Myocardial oxygen consumption was calculated as the
product of oxygen extraction and the blood flow. The content of glucose transporters in
either sarcolemma or intracellular membrane fraction was expressed as the binding per
microgram protein calculated from the density (dpm/|ig protein) product of the dpm of
l25-I-protein A and measured protein yield of that fraction (pg/g tissue) or expressed as
the relative content of transporters of each fraction)
All values are expressed as mean+/- SEM. Paired t test was used to compare
AICAR and control values. A value of p < 0.05 was considered significant.
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IV. RESULTS
Myocardial AICAR and Nucleotide Levels and AMPK Activity
During AICAR infusion in the LAD, the venous concentrations in the LAD region were
2510pM (+/- 78) as compared to 353|iM (+/- 55) in the LCX region at the end of the 90
minute period (table 2) There was a wide range in concentrations, reflecting changes in
flow. The medians were 1897(iM in the LAD region and 1 78jlxM in the LCX region. A
value of 1399(iM in the LCX region (compared to 2280JJ.M in the LAD region) in one
sample, probably due to the presence of venous collaterals that were inaccessible for
suturing and separating, caused the average overall LCX region AICAR concentration to
be much higher. The concentration of ZMP was 321pM (+/- 69) in the AICAR region
and 158 pM (+/-34) (P < 0.05). There was no significant difference in the concentrations
of AMP, ADP, or ATP levels (Table 2).
AICAR infusion resulted in a significant 3-fold higher AMPK activity in the
anterior region (73pmol/min/mg to 253pmol/min/mg) as compared to the LCX region
which did not receive AICAR (figure 4).
Subcellular Membrane Distribution of GLUT-1 and GLUT-4
Analysis of western blots show that both GLUT-1 and GLUT-4 were found primarily in
the intracellular compartment in regions of myocardium that did not receive AICAR. As
determined by activity of the bands and yield of each fraction (see Methods), the
sarcolemma contained 30% of GLUT-1 and 22% of GLUT-4, (figures 5, 6)
In the region that received AICAR, there was evidence of translocation of both glucose
transporters from the intracellular pools to the sarcolemma. The relative sarcolemma
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distribution of GLUT-4 increasd 2-fold to 40% (P<.002) while that of GLUT-1 increased
two-thirds to 50% (p<.001). (figures 5, 6) The ratio of sarcolemmal to intracellular
transporter densities increased significantly for both GLUT-1 (0.75 to 1.3, p<0.0007) and
GLUT-4 (0.35 to 0.68, p< 0.009). (table 3)
Myocardial Metabolism in vivo
Arterial concentrations of FFA, lactate, and oxygen content did not change during the
local intracoronary infusion of AICAR . However, there was a significant decrease in
glucose concentration following AICAR infusion at 45 minutes and 90 minutes, (table 4)
The systemic arterial concentrations of AICAR were 93pM at 45 minutes and 123p.M at
90 minutes. These AICAR concentrations are approximately 5% of the concentrations in
the LAD bed and are not known to affect glucose concentration and is there not the likely
cause of the drop in glucose concentration observed.

Other systemic changes may be

have caused a small hypoglycemic effect. Insulin levels were not determined. The
AICAR region showed a 2-fold increase in myocardial glucose uptake, extraction, and
arterial-venous difference (AVD) in the AICAR (LAD) regions when compared with the
control (LCX) region after 90 minutes of AICAR infusion, (table 4, figure 8) There was
a modest (approximately 30%) increase in FFA uptake, extraction, and AVD after 90
minutes of infusion. There was a similar change after 45 minutes, although the AVD did
not reach significance, (table 5) Prior to the administration of AICAR, the uptake,
extraction, and AVD of glucose and FFA was similar in the two regions. Lactate and
oxygen uptake showed no significant difference either in baseline period, at 45 minutes
or at 90 minutes, (tables 6, 7) The myocardial uptake, extraction, and AVD of glucose
and oxygen consumption were not significantly different in LCX (control) region or in
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the LAD region following administration of AICAR in the LAD. However, there was
significantly higher FFA extraction at 90 minutes of AICAR infusion when compared to
baseline in the LAD region and a significantly lower lactate AVD in the LAD region at
45 minutes and at 90 minutes of infusion when compared to baseline.
Glycogen, citrate, G6P, and creatine phosphate levels were not significantly
different in the AICAR and control regions.(table 2)
Hemodynamics and Myocardial Thickening
Infusion of AICAR in the LAD region had no effect on thickening fraction when
compared to the control LCX region, (table 8, 9) However, there was statistically
significant, 25% decrease in the thickening fraction of the LAD region following 90
minutes of AICAR infusion, (table 9) Heart rate, mean arterial pressure, dP/dt and
LVEDP were unchanged during AICAR infusion when compared to baseline
Following AICAR infusion, there was a trend (P = 0.06) for higher blood flow in the
AICAR perfused LAD region when compared with the LCX region. (Table 9) There
was no change in blood flow following 45 minutes of AICAR infusion. (Table 8).
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Table 2. Myocardial Tissue Concentrations of AICAR,
Nucleotides, Glycogen, G6P, Citrate, and Creatine Phosphate
Control

AICAR (pM)

353 (+/-55)

ZMP (pM)

158 (+/- 34)

AMP (pM)

28 (+/- 548)

ADP (pM)

1098 (+/-114)

ATP (pM)

3740 (+/-194)

Creatine Phosphate (mM)

9.0 (+/- 3.6)

G6P (pM)

254 (+/-15)

Citrate (pM)

535 (+/-35)

Glycogen (pM/g)

28 (+/-5.3)

Values are means +/- SEM (n=4-6). *P< 0.05 vs Control.

AICAR (90min)

2511 (+/- 78) *

321 {+1-69 ) *

19 (+/- 119)

1217 (+/- 183)

4350 (+/- 249)

8.4 (+/- 2.4)

271 (+/- 19)

410 (+/-28)

32 (+/-4.5)

pmol/min/mg

AMPK Activity

CONTTROL

AICAR

Figure 4. AMPK activity in control and AICAR infused
myocardium. Values are expressed +/- SEM (n=3).
* P< 0.05
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GLUT 1 (% SL)

CONTROL

AICAR

Figure 5. Percentage of GLUT1 in sarcolemma
in myocardium from control and AICARperfused regions. Values are mean +/- SEM. *
P < 0.005 vs control region.
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GLUT 4 (% SL)

CONTTROL

AICAR

Figure 6. Percentage of GLUT4 in sarcolemma in
control and AICAR perfused myocardium. Values
are mean +/- SEM. * P < 0.001 vs control.
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IC SL
Control
AICAR

Figure 7a. GLUT4 immunoblot of intracellular and sarcolemma
membranes.

SL
Control
AICAR

Figure 7b. GLUT1 immunoblot of intracellar and sarcolemma
membranes.
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Table 3. Effect of AICAR on GLUT1 and GLUT4 Distribution
in Intracellular (IC) and Sarcolemmal (SC) Fractions
Control

AICAR

GLUT1 IC:SL

0.7 (.12)

1.3 (0.16)*

GLUT1% SL

30 (6.4)

50 (4.7)*

GLUT4 IC:SL

0.4 (0.09)

0.8 (0.05)*

GLUT4% SL

22 (6.1)

39 (6.6)*

Values are expressed as mean +/- SEM. * P< 0.005 vs Control.
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Table 4 Effect of AICAR on Arterial Concentration, ArterialVenous Difference,Extraction and Uptake of Glucose.

A-V Difference

Arterial

LAD

LCX

Baseline

6.02 (0.24)

3.46 (0.067)

2.83 (0.058)

45 min

5.52 (0.23)**

3.81 (0.052)

3.54 (0.054)

90 min

5.37 (0.23)**

3.95 (0.059)*

2.09 (0.043)

Extraction:

LAD

LCX

Baseline

3.2 (1.01)

2.7 (0.96)

45 minutes

3.8 (0.91)

3.7 (1.06)

90 minutes

4.09 (1.08)*

2.2 (0.87)

Uptake:

LAD

LCX

Baseline

13.1 (4.3)

10.5 (3.8)

45 minutes

13.5 (3.4)

9.9 (2.6)

90 minutes

13.6 (3.3)*

5.9 (2.1)

Arterial concentration and A-V difference in mM. Extraction is in %/100. Uptake is in
pmol/lOOg/min. . Values are expressed as mean +/- (SEM). * P< 0.005 vs Control/
LCX. **P<0.05 vs Baseline.

umoi/IOOg/min

GLUCOSE UPTAKE

Figure 8. Uptake of glucose in myocardium from
control and AICAR infused regions. Data are
quantified as umol/IOOg/min. Values are mean +/SEM (n=8). *P< 0.05
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Table 5 Effect of AICAR on Arterial Concentration, ArterialVenous Difference, Extraction and Uptake of FFA.

Arterial

A-V Difference
LAD

LCX

Baseline

635 (106)

174 (41)

163 (46)

45 min

527 (60)

193 (42)

164 (32)

90 min

507 (43)

207 (25)*

176 (26)

Extraction:

LAD

LCX

Baseline

27 (4.4)

22 (3.0)

45 minutes

35 (4.3)

30 (3.4)

90 minutes

42 (4.2)* & **

34 (4.5)

Uptake:

LAD

LCX

Baseline

11.8 (2.5)

10.3 (2.0)

45 minutes

13.3 (2.5)

9.1 (1.1)

90 minutes

13.7 (2.0)*

10.0 (1.5)

Arterial concentration and A-V difference in jiM. Extraction is in %/100. Uptake is in
pmol/lOOg/min.. Values are expressed as mean +/- (SEM). * P< 0.005 vs Control.
**P<0.05 vs Baseline.
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Table 6 Effect of AICAR on Arterial Concentration, ArterialVenous Difference, Extraction and Uptake of Lactate.

Arterial

A-V Difference
LAD

LCX

Baseline

1.53

0.44 (0.074)

0.37 (0.067)

45 min

1.46

0.23 (0.062)**

0.27 (0.063)

90 min

1.62

0.24 (0.055)**

0.29 (0.065)

Extraction:

LAD

LCX

Baseline

29.4 (3.2)

26.8 (3.4)

45 minutes

15.2 (3.7)

17.9 (3.4)

90 minutes

13.9 (2.7)**

16.5 (4.1)

Uptake:

LAD

LCX

Baseline

27.5 (4.5)

23.1 (3.9)

45 minutes

16.3 (3.9)**

16.8 (3.8)**

90 minutes

12.3 (3.2)**

13.6 (3.2)

Arterial concentration ana a-V amerence in mivi. extraction is in Vo/iuu. uptake is in
|imol/100g/min.. Values are expressed as mean +/- SEM. * P< 0.005 vs Control.
**P<0.05 vs Baseline.
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Table 7 Effect of AICAR on Arterial Oxygen Content and
Oxygen Consumption.

Arterial

Oxygen Consumption
LAD

LCX

Baseline

15 (1.5)

6.7 (1.5)

5.8 (0.7)

45 min

15 (0.7)

6.6 (1.4)

5.6 (0.7)

90 min

15 (0.9)

8.9 (0.8)

8.4 (0.9)

Values are in ml/lOOg/min. Values are expressed as mean +/- SEM. * P< 0.005 vs
Control. **P<0.05 vs Baseline.
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Table 8. Myocardial Contactile Function and Hemodynamics
during Baseline and after 45 Minutes of AICAR Infusion
Baseline

AICAR

Thickening Fraction, %
Control Region

17 (+/- 1.6)

17(4-/- 1.5)

AICAR Region

20 (+/- 0.8)

19 (+/- 0.8)

Heart Rate, bpm

113 (+/- 5.4)

112 (+/-6.4)

Mean Arterial Pressure, mm Hg

82 (+/- 3.4)

83 (+/- 3.3)

LVEDP, mm Hg

10 (+/- 1.2)

10(+/- 1.1)

dP/dt, mm Hg/s

1297 (+/- 99)

1239 (+/- 99)

Blood Flow, ml/g/min
Control Region

1.01 (+/-0.08)

0.97 (+/- 0.22)

AICAR Region

1.01 (+/- 0.08)

1.01 (+/- 0.17)

Values are means +/- SEM. * P < 0.05 vs Baseline Period. ** P = 0.06 vs Control
Region.
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Table 9. Myocardial Contactile Function and Hemodynamics
during Baseline and after 90 Minutes of AICAR Infusion
Baseline

AICAR

Thickening Fraction, %
Control Region

17 (+/- 1.6)

16(+/- 2.7)

AICAR Region

20 (+/- 0.8)

16 (+/- 0.5)*

Heart Rate, bpm

113 (+/- 5.4)

117 (+/-6.8)

Mean Arterial Pressure, mm Hg

82 (+/- 3.4)

79 (+/- 6.2)

LVEDP, mm Hg

10 (+/- 1.2)

9 (+/- 1.3)

dP/dt, mm Hg/s

1297 (+/- 99)

1062 (+/- 97)*

Blood Flow, ml/g/min
Control Region

1.01 (+/-0.08)

0.81 (+/- 0.14)

AICAR Region

1.01 (+/- 0.08)

1.01 (+/- 0.17)**

Values are means +/- SEM. * P < 0.05 vs Baseline Period. ** P = 0.06 vs Control
Region.
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V. DISCUSSION
AMPK Activation, Stimulation of Glucose Transport and Transporter
Translocation
This study demonstrates two important findings. First, it shows that activation of AMPK
by AICAR results in a two-fold increase in myocardial glucose uptake in vivo. Second, it
demonstrates that this increase in glucose uptake is associated with translocation of heart
GLUT 4 and GLUT 1 glucose transporters from an intracellular pool to the sarcolemma
suggesting that the increased glucose uptake is at least in part mediated by transporter
translocation. Since myocardial ischemia and hypoxic stress or contraction in skeletal
muscle are also known to activate AMPK and stimulate glucose uptake through glucose
transporter translocation, this study supports the hypothesis that ischemia mediated
changes in glucose may also be mediated by this kinase.
AICAR, an intermediate in the purine biosynthetic pathway, is taken up by cells
and phosphorylated to form ZMP which mimics the effects of intracellular AMP causing
allosteric activation of AMPK and promoting phosphorylation and covalent activation of
AMPK by AMPK kinase. [Corton, 1995 #26] In this study, local intracoronary infusion
of AICAR achieved concentration of approximately 2mM in the venous blood draining
from the infused region. AICAR was taken up by the heart and was phosphorylated to
form ZMP. The myocardial ZMP concentration averaged 310p,M which approximates
the concentration causing the half maximal activation of AMPK in vitro. [Henin, 1996
#48] Significantly, the concentrations of the substrates which normally determine AMPK
activity, AMP, ATP, and ADP as well as creatine phosphate were unchanged indicating
that the changes in AMPK activity were not an indirect effect of AICAR altering the

.
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energetics of cardiac myocytes but rather a likely direct effect through conversion to
ZMP.
Our findings demonstrated a 2-3 fold increase in the myocardial glucose uptake
associated with AMPK activation during local intracoronary AICAR infusion in vivo.
This is comparable to the 3-4 fold increase in glucose uptake observed during low flow
ischemia in the same canine model using a similar protocol and measurement techniques
in our laboratory. [Young, 1995 #79] Other studies of AMPK stimulation by AICAR
also found similar effects on glucose uptake. In perfused hindlimbs, AMPK stimulation
by AICAR led to a several fold increase in glucose uptake. [Merrill, 1997 #51] In vivo,
systemic infusion of AICAR at a rate of 7.5 mg/kg achieved an average ZMP
concentration of 350pM, similar to the concentration in the AICAR perfused region in
our study, and stimulated skeletal muscle glucose uptake two fold. [Bergeron, 1998 #86]
In recent in vitro studies, we observed that incubation of isolated quiescent rat papillary
muscles in ImM AICAR caused a two-fold increase in deoxyglucose uptake. [Russell,
1998 #44] Thus the findings in the intact heart in this study are congruent with these
earlier studies and further demonstrate the enhancement of myocardial glucose uptake in
hearts performing a physical workload while also subject to the influence of circulating
hormones.
This study found that AICAR infusion is associated with translocation of
myocardial GLUT4 and GLUT1 from intracellular pools to the sarcolemma. This
suggests that, in myocardium, AICAR stimulates glucose uptake by increasing the
number of facilitative glucose transporters available at the sarcolemma. We have
recently found that AICAR also stimulates translocation of GLUT4 to the sarcolemma
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using immunoflorescence in quiescent rat papillary muscles.

These studies were in non¬

working myocardium and in an artificial hormonal and substrate milieu. This the first
demonstration of AICAR induced translocation of GLUT4 in vivo and the initial
evidence that AMPK stimulation by AICAR causes translocation of GLUT1 as well.
AICAR caused an increase in the sarcolemmal content of GLUT4 from 22% to
40%. Exercise or skeletal muscle and myocardial ischemia also cause translocation of
glucose transporters.

In our previous studies, [Young, 1995 #79] low flow ischemia led

to a doubling of the distribution of GLUT4 in the sarcolemma increasing from 15% to
30%.

While it had been suggested that only GLUT4 translocation is involved in the

response of muscle to exercise/contraction GLUT1 also plays a role in cardiac muscle.
[Douen, 1990 #65; Hayashi, 1997 #17] GLUT1 is only found in the sarcolemma of
adipocytes and skeletal muscle and is not thought to be “recruitable” in these tissues.
However, in myocardium we have previously found that GLUT1 is responsive to
ischemia though to a lesser extent than GLUT4. Low flow ischemia caused the
proportion of GLUT1 in the sarcolemma to increase by 41% to 58%.

This is somewhat

less than the effect of AICAR and AMPK activation which increased GLUT1
sarcolemma from 30% to 50%. [Young, 1995 #79] This provides further evidence that
GLUT1 plays a unique role in myocardium in that it is recruitable and responds to stimuli
to increase uptake of glucose. This is likely due to the large metabolic demands of
myocardium.
AMPK Activation in Muscle
AICAR infusion stimulated AMPK activity by three fold. There is evidence
which suggests that AMPK activation plays a key role in the response to oxidative stress

45

in both skeletal and cardiac muscle whether during contraction/exercise or ischemia.
The highest levels of mRNA are found in skeletal and cardiac muscle. [Verhoweven,
1995 #53] In skeletal muscle of rats, prolonged exercise led to a several fold activation of
AMPK and a subsequent inactivation of ACC and repression of malonly CoA. [Winder,
1996 #34] In perfused working rat hearts subject to global ischemia, there was a large
increase in AMP levels and a 2-3 fold activation of AMPK. [Kudo, 1995 #36] AMPK
activity remained high even after reperfusion reflecting, perhaps the continuing effects of
AMPK phosphorylation. [Kudo, 1995 #36; Kudo, 1996 #24] Many other studies have
demonstrated a stimulation of AMPK in response to exercise/contraction or ischemia
[Hutber, 1997 #39; Vavvas, 1997 #80]
Given that both ischemia and AICAR infusion stimulate glucose uptake and
translocation of GLUT4 and GLUT1, it is intriguing to consider that ischemia induced
translocation of glucose transport and is mediated through AMPK.

While the

mechanism through which ischemia in myocardium and exercise/contraction stimulate
glucose uptake and glucose transport translocation is not known, it is characterized by
several observations demonstrating that it is distinct from the well studied insulin
regulated increase in glucose uptake and glucose transporter translocation.

Insulin binds

to the a-subunit of the insulin receptor which leads to phosphorylation of the (3-subunit
and increased tyrosine kinase activity. Tyrosine kinase phosporylation of the
intracellular insulin receptor substrate-1 (IRS-1) then causes activation of
phosphatidylinositol-3-kinase(PI3 K). (figure 9) [Holman, 1997 #54] This kinase is
inhibited by wortmannin and the action of insulin in stimulating glucose uptake and
translocation is also inhibited in both skeletal muscle and cardiac muscle. [Lee, 1995
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#61; Russell, 1998 #44; Hayashi, 1998 #50]This is in contrast to the ischemia mediated
and exercise/contraction mediated increase in glucose uptake [Russell, 1998 #44;
Bergeron, 1998 #86] and translocation in skeletal muscle which is not influenced by
PI3K inhibition by wortmannin. Wortmannin did not block the stimulation of glucose
uptake by AICAR in skeletal muscle [Russell, 1998 #44; Bergeron, 1998 #86] and in
isolated papillary muscles. [Russell, 1998 #44] A second observation which suggests a
distinct pathways in insulin and ischemia/exercise stimuated glucose uptake is the
additive nature of insulin and ischemia/contraction. AICAR and ischemia are not
additive but AICAR and insulin are additive in skeletal muscle. [Bergeron, 1998 #86]
Finally, our study bolsters the hypothesis because pharmacological AMPK stimulation
was shown to cause translocation and increased transport in vivo in physiologic
conditions.
Other pathways for the ischemia mediated glucose transport have been
hypothesized.

Due to the role of PI3K in insulin mediated on glucose, a potential role

for the kinase in ischemia/contraction was hypothesized in muscle. However, studies of
PI3K inhibition suggest that it is not a mediator in ishcemia/contraction. [Egbert, 1997
#41; Lund, 1995 #43] Protein kinase B (Akt) has been identified as a downstream target
for PI3K in the insulin mediated GLUT4 translocation and it may serve as a target for
AMPK as well. [Hayashi, 1997 #17] Since calcium plays a key role in muscle
contraction, it has also been proposed as a mediator of translocation. [Holloszy, 1996
#19] While calcium has been shown to increase glucose transport in isolated muscle and
blockade of calcium release from sarcoplasmic reticulum blocks glucose transport,
calcium stimulated glucose transport does not share one a key characteristic of
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exercise/ischemia mediated glucose uptake—it inhibits insulin induced glucose transport
in contrast to exercise/ischemia induced glucose transport which is additive to insulin.
[Draznin, 1987 #60; Lee, 1995 #61]
Several kinases have been proposed as mediators of exercise/contraction
stimulation of glucose uptake. Inhibition of PKC by phorbol esters has been shown to
decrease contraction stimulated glucose transport in skeletal muscle in vitro. [Cleland,
1989 #62] Exercise also activates the mitogen-activated protein kinase (MAP kinase).
[Aronson, 1997 #64] But this mechanism is unlikely given recent that demonstration that
pharmacological blockade of MAP kinase does not influence contraction stimulated
glucose transport in vitro . [Hayashi, 1998 #50] Other kinases proposed to be involved in
GLUT4 translocation include the c-Jun NH2 terminal kinase and p38 kinase. [Hayashi,
1997 #87] These kinases may mediate the effects of ischemia and AICAR in stimulating
GLUT4 translocation, (figure 9)
Other changes that result from ischemia may also mediate the effects of ischemia
Nitric oxide is released during skeletal muscle contraction and inhibition of nitric oxide
synthase has been demonstrated to inhibit contraction mediated glucose transport but not
insulin stimulated glucose transport. [Kapur, 1998 #57; Balon, 1997 #55] Other potential
regulators of glucose transport include bradykinin [Kishi, 1998 #88] and kallikrein and
adenosine. [Han, 1998 #56; Law, 1988 #58] While nitric oxide, bradykinin, and
kallikrein are potential mediators of AICAR induced stimulation of glucose transport, it
is unlikely since no potential mechanism whereby AICAR influences them has been
identified. Since AICAR may increase local concentrations of adenosine and is
structurally similar to adenosine, it is possible that its actions may be mediated by acting
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AMPK Activation
Figure 9 Schematic presentation of the potential mechanisms of insulin and ischemia induced GLUT4
translocation. Yellow circles are representations of insulin sensitive GLUT4 vesicles with specific
makers such as Rab4 (orange). Pink circles represent ischemia and/or AMPK sensitive GLUT4 vesicles.
IR is the insulin receptor. Blue represents GLUT4 transporters.
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on adenosine receptors. However, AICAR is not known to act on adenosine receptors
and inhibition of these receptors does not affect AICAR stimulation of glucose uptake.
[Russell, 1998 #44]
Downstream Mechanisms of GLUT4 Translocation
The downstream mechanisms responsible for AMPK mediators are unclear.
Studies from the insulin mediated transport indicate that there are many potential
mechanisms by which AMPK may effect glucose translocation. GLUT4 cycles between
the plasma membrane and intracellular compartments with most staying intracelluarly in
the basal state. [Kandror, 1996 #67] Stimulation of glucose uptake can be effected either
through an increase in the rate of GLUT4 vesicle exocytosis or by a decrease in
endocytosis. [Stephens, 1995 #10] Insulin acts largely by stimulating exocytosis, causing
a 10-20 fold increase in exocytosis compared to only a 2-3 fold decrease in the rate of
endocytosis.

GLUT1 is distributed more evenly between the intracellular compartment

and the sarcolemma and plays a smaller role in altering glucose transport in response to
extracellular signals. [Young, 1995 #79; Fischer, 1997 #21] Insulin causes a more modest
stimulation of GLUT1 and exercise has been reported not to influence GLUT1 in skeletal
muscle but we have previously shown that ischemia in myocardium, like AICAR, does
cause translocation of GLUT1, though to a more modest degree. [Young, 1995 #79]

GLUT4 Vesicles
There is evidence which suggests that GLUT4 vesicles are heterogeneous. The
additive nature of exercise and insulin mediated effects on glucose transport and GLUT4
translocation suggest there may be further or separate pools of GLUT4 vesicles that are
more responsive to specific stimuli. [Douen, 1990 #65] Novel membrane fractionation
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techniques in cultured adipocytes have identified distinct intracellular locations or pools
of glucose transporters, one responsive to exercise and another more responsive to
insulin. [Hayashi, 1997 #17; Coderre, 1995 #63] Rab4, a GTP binding protein involved
in formation, targeting, and fusion of vesicles by acting as a molecular switch by
interconversion, from a GDP-bound form to a GTP-bound form [Van der Sluijs, 1992
#89] is redistributed by insulin but not by exercise. [Hayashi, 1997 #17; Sherman, 1988
#90] It is possible that GLUT4 carrying vesicles have unique receptors making them
more sensitive to particular stimuli.
Regardless of whether GLUT4 vesicles are segregated by responsiveness to
stimuli or not, GLUT4 transporters require specific signals to be properly targeted for
intracellular storage. [Pessin, 1999 #66] Recent studies suggest that the cytoplasmic Cterminus of GLUT4 contains a dileucine motif whose absence leads to accumulation of
GLUT4 in the plasma membrane[Verhey, 1995 #82]. This sequence has been shown to
be involved in internalization and while similar motifs responsible for sequestration have
not been identified, morphologic and kinetic studies suggest they are present in the
GLUT4 cytoplasmic C-terminus. [Pessin, 1999 #66]

GLUT4 Exocytosis
A recent review proposes two major, overlapping mechanisms whereby insulin
and other stimimuli can regulate GLUT4 exocytosis . [Pessin, 1999 #66] The first,
“retention model” (figure 10) suggest that GLUT4 vesicles participate in the
constituitively recycling endosomal system with regulation of exocytosis by regulation of
GLUT4 vesicles through specialized “retention receptors” that control their entry into the
endosomal system.

GLUT4 protein is localized in small vesicles and tubulovesicular
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structures with lesser amounts in the trans-Golgi network, clathrin-coated vesicles and
endosomes. [Rodnick, 1992 #68; Slot, 1991 #69] GLUT4 vesicles and tubulovesicular
are found adjacent to endosomes underlying plasma membrane. [Pessin, 1999 #66] For
insulin induced translocation, the insulin-responsive aminopeptidase (IRAP), also known
as vpl65, may act as a retention receptor. IRAP is known to probably co-localize with
GLUT4 vesicles and displays some homology with the GLUT4 C-terminus. [Kandror,
1994 #73] In addition, introduction of the cytoplasmic domain of IRAP results in plasma
membrane translocation of GLUT4. [Waters, 1997 #91] Despite the evidence supporting
the role of the recycling endosomal system and sequestering, retention receptors, there
are other findings which suggest that this model does not account for all the regulation of
iGLUT4 trafficking. GLUT4 containing vesicles can be differentiated from the
constituitively recycling endosomal system. GLUT4 vesicles are enriched in the vSNARE (vesicle SNAP receptors) protein , VAMP2 but not the VAMP3 isoform present
in the constituitively recycling endosome population. [Martin, 1998 #71] Furthermore,
ablation of the endosomal population as tracked by the transferrin receptor suggest that
insulin-stimulated GLUT4 translocation can occur independent of the endosomal system.
This finding with insulin may also be true with ischemia.
Protein complexes in the GLUT4 vesicle compartment such as the v-SNARE
VAMP2 suggest that a synaptic-like mechanism similar to that found in the vesicle
trafficking regulation of neurotransmitters may regulate GLUT4 vesicle transport.
[Pessin, 1999 #66] (figure 11) v-SNAREs pair with their matching receptor complexes at
the target membrane (called t-SNAREs for target SNAP receptors). Interaction between
v-SNAREs and t-SNAREs in combination with accessory proteins is responsible for

52

IR

Ischemia,
AMPK activation

Figure to. Schematic illustration of retention hypothesis of GLUT4 trafficking. GLUT 4
vesicles are sequestered by association with retention receptors (RR). Insulin or other
stimuli such ischemia or AMPK activation can cause dissociation from RR and entry of
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Figure \ \. Schemtic presentation of the hypothesized synaptic model of GLUT4 trafficking.
GLUT4 vesicles are localized to small synaptic like vesicles and larger tubulovesicular compart¬
ments in equilibrium. Both have the v-SNARE VAMP2. GLUT4 translocation can be induced by
interaction of VAMP2 with t-SNARE complex. (Blue figures represent GLUT4. GLUT4 at plasma
membrane not shown).
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determining trafficking and formation of complexes required for membrane fusion
[Pessin, 1999 #66] . VAMP2 has been identified on GLUT4 vesicles and may act as the
v-SNARE protein while studies using blocking antibodies, dominant interfering mutants
and peptide inhibitors suggest that several proteins (including syntaxin 4 and
SNAP23/Syndet) act as the t-SNARE proteins. Muncl8c and Synip have recently been
shown to bind to syntaxin 4 and may be part of the complex that regulates the interaction
with VAMP2. Binding of Muncl8c to syntaxin 4 prevents its binding to VAMP2 and an
increase in expression of Muncl8c inhibits insulin-stimulated GLUT4 translocation.
While the precise role of Synip has not been delineated, it interaction with syntaxin 4 is
known to be regulated by insulin.

Role of G-Proteins and GLUT4 Endocytosis
There is a role for G-proteins in GLUT4 trafficking but the specific mechanisms
have not been elucidated. GTPyS causes GLUT4 translocation [Pessin, 1999 #66] and Gprotein coupled receptors linked to Gq can also induce GLUT4 translocation. [Kishi,
1998 #88] Signalling intermediates such as Grb2 involved in G-protein signal
transduction are also known to interact with IRS 1, a key intermediary of insulin
stimulated translocation through PI3K. [Holman, 1997 #54]
G-proteins may have an especially significant role in GLUT4 endocytosis.

In the

basal state, GLUT4 in plasma membrane is in coated pit regions and disruption of
clathrin has established a role for clathrin-mediated edocytosis in GLUT4 internalization.
GTPase dynamins are essential to this process and in addition to GTPase sites have
domains which interact with signaling intermediates such inositol phospholipids and
amphiphysin. [Volchuk, 1998 #77] Dynamin may play an important role in regulating
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Exocytosis

Figure 12- The internalization of GLUT4 occurs through a dynamin-dependent mechanism. After
translocation, GLUT4 accumulates in clathrin-coated (orange) invaginations of the plasma membrane. This
occurs through the interaction of of GLUT4 with complexes such as AP2 (red circle). Dynamin (green
rectangle) is recruited to thesese structures and is required for the intracellular clathrin coated vesicles.
These vesicles rapidly lose their coat structure and are available for translocation or to repopulate the
intracellular pool of GLUT4 vesicles.
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GLUT4 endocytosis and may serve as a target of AMPK phosphorylation, (figure
12) Insulin has been reported to induce tyrosine phosphorylation of dynamin [Baron,
1998 #75]and microinjection of a dynamin peptide encompassing anphiphysin binding
sites prevents GLUT4 edocytosis and cause accumulation in the sarcolemma. [Volchuk,
1998 #77]Expression of a dominant interfering mutant of dynamin has also been shown
to prevent GLUT4. [Al-Hasani, 1998 #76] This GTPase may thus be a target for AMPK
phosphorylation.
Fate of glucose
While AICAR infusion increased myocardial glucose uptake, our findings do not
define the fate of the glucose. Once in the cell as G6P there are four potential fates of
glucose: glycogen synthesis, glycolysis, glucose oxidation or the pentose phosphate
shunt. G6P concentrations were unchanged in the AICAR regions, indicating that any
increase in glucose conversion to G6P was balanaced by increased distal metabolism.
Although AMPK inhibits glycogen synthase and stimulates glycogen phosphorylase in
liver effectively decreasing synthesis and increasing breakdown, [Gillespie, 1992 #92] it
does not affect glycogen synthase in musle but still stimulates glycogen phosphorylase
leading to increased glycogenolysis. [Young, 1996 #93] However, in the rat, intravenous
AICAR infusion does no affec skeletal muscle glycogen. [Bergeron, 1998 #86] But in
myocardium it appearst to increase muscle glycogen. [Russell, 1998 #44] The latter effect
may be due to preferential flux of glucose into glycogen which may occur due to the
increase in arterial lactate concentrations accompanying AICAR infusion. [Russell, 1998
#44] We saw a fall in arterial lactate suggesting that the glucose was not released as an
end product of glycolysis.
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Oxygen uptake was not stimulated in the AICAR region. Increased glucose
oxidation could be expected to stimulate oxygen uptake, especially in light of the
enhanced FFA uptake that is also likely to have been oxidized (see below). The energy
content of the cell as measured by creating phosphate and ATP did not change. These
findings suggests that AICAR did not stimulate glucose oxidation.

A potential fate of

glucose is to enter the pentose phosphate shunt to provide NADPH for reductive
biosynthesis. The activity of this pathway is very low in muscle [Stryer, 1995 #84] and
unlikely to be the primary fate of the additional glucose that is taken up. It is important
to note that if the glucose did not become metabolized through a single pathway, the
measurement techniques we used may have been inadequate to record several small
changes.
Effect on FFA
Our study found a small increase in FFA uptake following AICAR infusion. This
is consistent with previous studies which showed a stimulation of FFA entry into
mitochondria due to an increase in CPT1 activity caused by a decrease in malonyl-CoA
levels which resulted from the phophorylation of ACC and a 50% increase in FFA
oxidation. [Kudo, 1995 #36] While we did not measure FFA oxidation or triglyceride
synthesis it is likely that the additional FFA was oxidized through the phosphorylative
inhibition of ACC. However, we did not see an increase in oxygen uptake.
Hemodynamics and Functional Effects
While there was a trend for higher blood flow in the AICAR infused region, the
overall myocardial contractility and cardiac output were significantly depressed
following region infusion of AICAR. Though much lower rates of systemic AICAR
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infusion were used, earlier investigators had found that AICAR had no functional effects
on non-ischemic myocardium [Young, 1991 #94; Gruber, 1989 #95] and improved
cardiac function in ischemic myocardium. [Young, 1991 #94; Gruber, 1989 #95]
Clinical studies also show a beneficial effect of AICAR on myocardial function.
A meta-analysis of 5 international randomized trials showed that intravenous infusion of
AICAR (O.lmg/kg/min) following surgery reduced perioperative myocardial infarction
by 27% and decreased the incidence of cardiac death by 50% in the postoperative period.
[Mangano, 1997 #96] Another study found that AICAR improved ventricular function in
pacing-induced ishcmia. [de Jonge, 1997 #97]
The mechanism for any functional effect of AICAR in ischemic myocardium is
not known but a role for increases in local concentrations of adenosine has been
postulated. [Gruber, 1989 #95] Despite the structural homology of AICAR with
adenosine, AICAR is not known to act on adenosine receptors and we did not measure
tissue or venous concentrations of adenosine. However, the functional effects that we
found are consistent with the known vasodilatory and negative inotropic effects of
adenosine receptor stimulation in myocardium. [Shryock, 1997 #98] Other investigators
[Gruber, 1989 #95] had not found an increase in adenosine concentrations in non¬
ischemic tissues.
Limitations of Study and Future Directions
The functional findings are limited by a lack of control animal experiments to
separate the potentially confounding effects of infusion and additional operative time
under anesthesia with open chest. While it was not a major aim of our study to
investigate these effects, additional studies with saline infused controls would clarify
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these findings. The control used in this study (LAD vs LCX) is not ideal because the two
arterial beds are not completely separated and communicate via collaterals. Moreover,
the extended period of study may allow AICAR to accumulate and cause systemic
effects. However the concentration of AICAR in the LAD (AICAR) bed was more than
seven fold higher than in the LCX (control) bed and more than 20-fold higher than in the
systemic circulation. The control bed was also not infused with saline and this may also
be a confounding variable. However, the rate of infusion is about 0.5% of the normal
canine coronary blood flow (0.25ml/min vs. 50ml/min) and unlikely to cause significant
disturbances in flow parameters.
The link between AMPK activation and glucose transporter translocation cannot
be unambiguously established.

We verified that AICAR infusion did lead to a

concentration of ZMP that is known to cause significant activation of AMPK and that the
enzyme was stimulated by infusion. However, while AICAR is known to activate
AMPK and has not been shown to cause any other effects on the cellular energy state, it
is possible that it has unidentified effects which may confound our findings. Experiments
with inhibitors of AMPK such as the ser-thr kinase inhibitor 5-iodotuberidon or genetic
techniques to suppress or overexpress the AMPK gene in myocardium would provide
further support for a role of AMPK in ischemia mediated changes in glucose transport.
This study provides the background necessary to pursue these investigations.
Conclusion
This study suggests that metabolic stress such as ischemia stimulate glucose
uptake by translocation of GLUT4 and GLUT1 through a mechanism that involves
AMPK. Additional studies are necessary to delineate the downstream effectors that lead

60

to translocation. This system may also mediate other the cellular and tissue responses to
ischemia.

Augmented stimulation of the system by AICAR or other potential stimulators

may enhance myocardial function during acute episodes of ischemia or in the long term,
may allow improvement of function by altering the metabolic milieu or other potential
mechanisms.
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